Menu

Focus On

SITI-2017-653x337px

SITI 2017 – FLORENCE

The 28th National Congress of the Italian Society of Intensive Care (SITI) takes place in Florence, Italy, November 16-18, 2017.

SITO-2017-653x337px

SITO 2017 – CAGLIARI

The 41st National Congress of the Italian Society of Organ Transplantation (SITO) takes place in Cagliari, Sardinia, Italy, November 9-11, 2017.

SIAART-2017-653x337px

SIAARTI 2017 – RIMINI

Estor will be present at the 71st National Congress of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI), 18 – 21 October 2017, Rimini, Italy.

SIN-2017-653x337px

SIN 2017 – RIMINI

Estor will be present at the 58th National Congress of the Italian Society of Nephrology (SIN), 4 – 7 October, Rimini, Italy.

Worls-Sepsis-Day-653x337px

WORLD SEPSIS DAY 2017

World Sepsis Day on September 13 aims to raise awareness of sepsis, an underestimated global healthcare problem affecting 31,500,000 people and causing 5,300,000 deaths annually.

ESICM-2017-653x337px

ESICM LIVES 2017 VIENNA

Estor will be present at the 30th ESICM LIVES 2017, 23 – 27 September, Vienna, Austria.
Come and meet us at our booth #206.

shutterstock_429243757_653x337

A message from WHO on sepsis

At the 70th World Health Assembly held on May 22nd-31st 2017 in Geneva, Switzerland, delegates agreed on a resolution to improve the prevention, diagnosis and treatment of sepsis, a global healthcare problem causing 5,300,000 deaths annually.

clinical-research-653x337

EUPHRATES RESULTS PRESENTATION – VICENZA COURSE 2017

At the 35th VICENZA COURSE on AKI and CRRT organized by Professor Claudio Ronco, held in Vicenza 13th–16th June, Professor Massimo Antonelli, President of the European Society of Intensive Care Medicine (ESICM) and member of the EUPHRATES trial steering committee, will present results from the EUPHRATES trial on Polymyxin B hemoperfusion in septic shock patients on 14th June at 17.30.

clinical-research-653x337

EUPHRATES trial – UPDATE

The fourth and final module of PMA application for FDA approval of Toraymyxin® has been submitted. A further data analysis of the EUPHRATES database identifies a population with significant mortality benefit when treated with Polymyxin B hemoperfusion therapy.